OptiBiotix Health PLC Launch of GoFigure range with Apollo Hospitals (0428V)
09 Diciembre 2021 - 01:00AM
UK Regulatory
TIDMOPTI
RNS Number : 0428V
OptiBiotix Health PLC
09 December 2021
OptiBiotix Health plc
("OptiBiotix" or the "Company" or the "Group")
Launch of GoFigure range with Apollo Hospitals in India
OptiBiotix Health India, a wholly owned subsidiary of OptiBiotix
Health plc (AIM: OPTI), a life sciences business developing unique
science and human study-based compounds that modulate the
microbiome to address metabolic syndrome and diabetes, systemic
low-grade inflammation, obesity, cardiovascular disease, high
cholesterol and to support healthy aging, has signed an exclusive
sales agreement with one of the leading hospital and pharmacy chain
Apollo Hospitals Enterprises Limited ("Apollo") for the sales of
its GoFigure weight management product range in India.
Apollo owns Apollo Pharmacies ( https://www.apollopharmacy.in/ )
which is one of the largest and most trusted branded pharmacy
network, with over 4,000 pharmacy outlets throughout India. The
in-store launch is expected to take place in February 2022 and will
progressively expand from there to other stores as well as online.
India is a region of strategic interest to OptiBiotix with a middle
class predicted to be the largest in the world by 2025 ( The rising
importance of the middle class in India - The Financial Express ,
March 2021).
GoFigure is OptiBiotix's direct-to-consumer (D2C) range of
weight management products which combines various meal replacement
and healthy snacking options including its multi award winning
weight management ingredient SlimBiome (R) . The initial product
launch will consist of meal replacement shakes and powdered
beverages and will be expanded over time.
This agreement is part of OptiBiotix' strategy to expand the
geographical footprint of its pro- and prebiotic business with
leading brands in the health & wellness market. It follows the
recruitment of Dr Taru Jain as Business Director India earlier in
the year (RNS: 19 January 2021) and the incorporation of OptiBiotix
India in recent weeks (RNS: 17 November 2021).
René Kamminga, C EO of O pti B i oti x Limited, c o mmented :
"We are very pleased to announce this agreement with Apollo, a
leading pharmacy chain in India. Our GoFigure range of weight
management products have been specifically formulated to support
consumers aiming to reduce their weight and help them stick to
their change in diet. We are very pleased that Apollo has selected
GoFigure as its range of weight management products of choice to
offer to its consumers . This launch is another important step in
building sales and brand presence for OptiBiotix' solutions with
major partners around the world."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Cenkos Securities plc (Broker) Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRFLFITFFLTIIL
(END) Dow Jones Newswires
December 09, 2021 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024